Navigation Links
Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
Date:8/25/2009

QUEBEC CITY, Aug. 25 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase I human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrollment of volunteers is now underway.

The Phase I placebo-controlled, double-blind, dose-escalating study will evaluate safety, tolerability and the immune response of the Company's H5N1 vaccine candidate in up to 48 healthy volunteers between the ages 18 to 60. Volunteers will receive two doses, injected 21 days apart of either a placebo or the influenza vaccine at doses of 5, 10 or 20 micrograms. The trial will take place at the Vaccine Evaluation Center of McGill University in Montreal, Canada, under the supervision of Dr. Brian Ward. Results of this study are expected during the fourth quarter of 2009.

"The acceptance of our Clinical Trial Application by Health Canada represents a major milestone in the company's development of novel influenza vaccines. It is a testament to the quality of our technology and demonstrates our ability to advance candidates towards human trials," said Andy Sheldon, President and CEO of Medicago. "This trial will be the first in which a plant-based vaccine will be injected into humans in Canada. We believe we have a compelling vaccine against influenza - a candidate, which at low dosage may protect against different strains of influenza that have the potential of becoming a pandemic. Combined with our rapid response and low cost manufacturing capabilities, we believe our vaccine can address an unmet gap in pandemic influenza preparedness efforts."

"All of our studies to date confirm that we have a safe and effective vaccine candidate entering human trials," said Nathalie Landry, VP Product
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicago initiates work on Swine Flu strain
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership
6. Foamix Receives US Patent on Novel Foam Technology
7. SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM)
8. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
9. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
10. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
11. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Working in collaboration with the National ... London , Richmond Pharmacology is the first centre worldwide ... for an investigational RNAi therapeutic being developed for the treatment ... and heart. Read press release ... at St Georges University of London , ...
(Date:3/27/2015)... Buffalo, New York (PRWEB) March 27, 2015 ... of the 2015 application period for 43North - the ... cash prizes, including a grand prize of $1 million, ... attracts entrepreneurs from around the world to compete for ... into funded enterprises in the Western New York region. ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... CINCINNATI , March 26, 2015 ... SHPG ) and Cincinnati Children,s Hospital Medical Center ... rare diseases. The goal of the collaboration is to ... diseases with high unmet medical need combining Shire,s ... expertise. As a nationally ranked hospital, Cincinnati Children,s ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5SQI Diagnostics Inc. Announces Adjournment of Meeting 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... BOTHELL, Wash., March 6 Cardiac Science,Corporation ... in advanced cardiac diagnosis,resuscitation, rehabilitation, and informatics ... of its leading product brands (Burdick(R),HeartCentrix(R), Powerheart(R), ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO ), "We ...
... (Pacific); ... SAN DIEGO, March 6 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on Thursday, March 13th, 2008 at 1:30 p.m. Pacific / 4:30 ... M.,Levine, chief executive officer and president of ADVENTRX, will host the,conference ...
... VANCOUVER, March 5 /PRNewswire-FirstCall/ - Dragon Pharmaceutical ... DRUG; BBSE: DRP), a leading,international pharmaceutical company ... production capacity for its core products 7ACA ... in order to meet increasing,demand from its ...
Cached Biology Technology:Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness 2Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness 3Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness 4Dragon announces new product launch; increase in annual production output capacity 2Dragon announces new product launch; increase in annual production output capacity 3Dragon announces new product launch; increase in annual production output capacity 4
(Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... SALT LAKE CITY, Nov. 15, 2012 ActiveCare, ... and diabetes management solutions, announced a dramatic decrease in ... relationship with Caprock HealthPlans. ActiveCare,s revolutionary health monitoring and ... specialists has lead to a healthier Caprock. By collecting ...
... available in Spanish . , Artificial logs that ... made from a perhaps surprising source: grass clippings. ... chemist Syed H. Imam and his colleagues have shown that lawn ... fire logs that burn brightly and evenly. The same formula can ...
... streams begins to occur at the initial stages of urban ... study found that streams are more sensitive to development than ... as fragile organisms, and yet that is exactly what the ... said USGS Director Marcia McNutt. "Streams are more than water, ...
Cached Biology News:Diabetes Management Provider ActiveCare Announces Cost Savings Of Over $4,000 Per Year Per Diabetic Member 2Fire logs made from lawn clippings offer earth-friendly option 2Streams show signs of degradation at earliest stages of urban development 2
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Biology Products: